Navigation Links
Ozarelix Phase 2 Data in Benign Prostatic Hypertrophy Presented at,Annual Meeting of American Urological Association

* Ozarelix Effective in Improving Symptoms and Urine Flow, With Long Lasting Effect in Phase 2 Study

IRVINE, Calif., May 23, 2007 /PRNewswire-FirstCall/ -- Spectrum Pharmaceuticals, Inc., today announced Phase 2 safety and efficacy data for ozarelix, the Company's drug candidate for the treatment of benign prostatic hypertrophy (BPH), at the American Urology Association Annual Meeting held at the Anaheim Convention Center in Anaheim, California on Tuesday, May 22, 2007.

"The results of this study indicate a significant and sustained degree of benefit, higher than what is usually seen with current treatments of BPH," said Rajesh C. Shrotriya, M.D., Chairman, President and Chief Executive Officer of Spectrum Pharmaceuticals. "We have recently completed enrollment in a Phase 2b study in the U.S. Once we have preliminary results from this Phase 2b trial, we plan to begin a Phase 3 trial, which we expect to begin later this year. Results from the Phase 2b trial will aid in the design of the Phase 3 trial. We believe that ozarelix could help serve the large unmet medical need for more effective BPH treatments."

The efficacy and safety of ozarelix, a GnRH antagonist, given intramuscularly (IM) was assessed in men with moderate to severe Lower Urinary Tract Symptoms (LUTS) due to BPH in a randomized, double-blind, placebo- controlled, multi-center, Phase 2 dose-ranging study.

Patients (N=144) meeting the inclusion criteria were randomly allocated to one of five treatment groups:

    Group 1:  placebo,

    Group 2:  5mg ozarelix on Day 1 + 5mg ozarelix on Day 15;

    Group 3:  10mg ozarelix on Day 1 +10mg ozarelix on Day 15;

    Group 4:  15mg ozarelix on Day 1 + 15mg ozarelix on Day 15; and,

    Group 5:  20mg ozarelix on Day 1 only.

Study participants were followed for six months. The primary efficacy endpoint was a change in the International Prostate Symposium Score (IPS
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. AEterna Zentaris Partner, Spectrum, Discloses Detailed Phase 2 Data for Ozarelix, in BPH at Annual AUA Meeting
2. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
3. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:6/30/2015)... Calif. , June 30, 2015  Ardelyx, Inc. ... on cardio-renal, gastrointestinal and metabolic diseases, today announced that ... July 14, 2015, from 8:00 a.m.- 1:00 pm EDT ... The Ardelyx senior management team will present ... lead compound, tenapanor, which has completed Phase 2b clinical ...
(Date:6/30/2015)... 30, 2015  July 4 th is this weekend, ... the spirit and people behind it. To help honor our ... USA Medical Card, a leading provider ... programs that empower independence for our disabled military veterans, police, ... people afford their prescriptions. "Due to ...
(Date:6/30/2015)... WAYNE, Pa. , June 30, 2015 ... ("Egalet"), a fully integrated specialty pharmaceutical company ... pain treatments, today announced top-line results from ... study of Egalet-002, an abuse-deterrent, extended-release, oral ... for the management of pain severe enough ...
Breaking Medicine Technology:Ardelyx to Host Inaugural R&D Investor Day in New York City on July 14, 2015 2Hope For Heroes and USA Medical Card Make a Difference for Our Nation's Heroes 2Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 2Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 3Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 4Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 5
... Misonix, Inc. (Nasdaq: MSON ), a developer ... which worldwide is used for acute health conditions, today ... year ending June 30, 2010.  Michael A. McManus, Jr., ... VP and Chief Financial Officer, will host a conference ...
... YORK, Sept. 28 Reportlinker.com announces that a new ... Global In Vitro Diagnostics (IVD) Market Report: ... The global IVD market has been experiencing ... has been growing awareness about health and prevention of ...
Cached Medicine Technology:Misonix Reports Fourth Quarter and Fiscal Year 2010 Financial Results 2Misonix Reports Fourth Quarter and Fiscal Year 2010 Financial Results 3Misonix Reports Fourth Quarter and Fiscal Year 2010 Financial Results 4Misonix Reports Fourth Quarter and Fiscal Year 2010 Financial Results 5Misonix Reports Fourth Quarter and Fiscal Year 2010 Financial Results 6Misonix Reports Fourth Quarter and Fiscal Year 2010 Financial Results 7Misonix Reports Fourth Quarter and Fiscal Year 2010 Financial Results 8Misonix Reports Fourth Quarter and Fiscal Year 2010 Financial Results 9Reportlinker Adds Global In Vitro Diagnostics (IVD) Market Report: 2010 Edition 2Reportlinker Adds Global In Vitro Diagnostics (IVD) Market Report: 2010 Edition 3Reportlinker Adds Global In Vitro Diagnostics (IVD) Market Report: 2010 Edition 4Reportlinker Adds Global In Vitro Diagnostics (IVD) Market Report: 2010 Edition 5
(Date:6/30/2015)... ... ... Ticket Down is a reliable source for last minute tickets for The Rolling Stones ... across North America in conjunction with their 2015 “Zip Code Tour.” , The Stones have ... in their twenties. Some of the most beloved songs that this iconic group has ...
(Date:6/30/2015)... ... June 30, 2015 , ... Earlier this month Wound Care ... Course. Clinicians from WCA partnering hospitals across the country, met in Anaheim, California ... and hyperbaric medicine education and training is something that is never complete. Even ...
(Date:6/30/2015)... ... June 30, 2015 , ... The LIV Fertility ... fertility preservation and deciding the right age to pursue egg freezing. Statistics show that ... age of 35 — a 150 percent increase since the 1970s. , Sadly, for ...
(Date:6/30/2015)... ... June 30, 2015 , ... University Post-Acute Rehab ... focuses on the rehab center’s patients and their experiences at the facility. Medicare ... of services available. Each patient attests to the high rating, which is predominantly ...
(Date:6/30/2015)... ... 30, 2015 , ... Lakeview Health, a drug and alcohol ... of its medical staff to further enhance its ability to treat addiction patients ... and physician assistants -- now totals 17, compared to 7 in 2013, the ...
Breaking Medicine News(10 mins):Health News:The Rolling Stones Tickets in Raleigh at Carter Finley Stadium: Ticket Down Offers Last Minute Tickets for the Rolling Stones and Avett Brothers in Raleigh 2Health News:Wound Care Advantage Hosts Its First UHMS Approved 40-Hour Introduction to Hyperbaric Medicine Course 2Health News:Wound Care Advantage Hosts Its First UHMS Approved 40-Hour Introduction to Hyperbaric Medicine Course 3Health News:LIV Fertility Center Educating Women on the Critical Timing of Egg Freezing 2Health News:LIV Fertility Center Educating Women on the Critical Timing of Egg Freezing 3Health News:LIV Fertility Center Educating Women on the Critical Timing of Egg Freezing 4Health News:LIV Fertility Center Educating Women on the Critical Timing of Egg Freezing 5Health News:Patients of University Post-Acute Rehab Support Five-Star Rating in New Video 2Health News:Lakeview Health, a Nationally Recognized Drug Rehabilitation Center in Florida, Doubles Size of Medical Staff 2
... half of U.S. children taken to hospital emergency departments (EDs) ... to ease worried parents, concerns. Yet true traumatic brain injury ... with minor blunt head trauma, led by Children,s Hospital Boston ... can reduce the use of head CT by as much ...
... N.Y. (May 9, 2011) In the first comprehensive study ... team of investigators from the U.S., South Korea, and Canada ... Korea to be 2.64%, or approximately 1 in 38 children, ... this approach is used to identify children with ASD. "Prevalence ...
... -- Celiac disease is more common among children born in ... from the Massachusetts General Hospital for Children. The ... may be related to a combination of seasonal and environmental ... by consuming the protein gluten, which is primarily found in ...
... In the wild, mammals survive because they can see ... That ability translates to the human world. Transportation Security Administration ... our messy and stuffed suitcases. We get out of the ... that cluttered shelf next to the door. This ability ...
... born in the spring or summer, and this higher ... seasonal and environmental factors, according to researchers at the ... of celiac disease is unknown, but potential triggers include ... viral infections during the first year of life. Researchers ...
... By Kathleen Doheny HealthDay Reporter , FRIDAY, May ... have higher blood glucose levels and a more difficult time ... 40 people with type 2 diabetes to 531 people without ... between sleep quality, blood glucose levels and other measures of ...
Cached Medicine News:Health News:Large study finds CT scans are frequently unnecessary after head injury in children 2Health News:Large study finds CT scans are frequently unnecessary after head injury in children 3Health News:New study reveals autism prevalence in South Korea estimated to be 2.6 percent or 1 in 38 children 2Health News:New study reveals autism prevalence in South Korea estimated to be 2.6 percent or 1 in 38 children 3Health News:Kids' Birth Month Seems to Be Linked to Celiac Disease: Study 2Health News:The brain performs visual search near optimally 2Health News:Season of birth and celiac disease in Massachusetts children 2Health News:Poor Sleep Might Worsen Diabetes 2
... Stainless steel spiral reinforced. X-ray opaque . Low ... Flange: The flange can be adjusted along the ... cervical soft tissue. The lock ring is turned ... the shaft. Maximum Patient Comfort: The tube is ...
... Per-fit™ tubes are a dual ... of the disposable inner cannula ... provided in the procedural tray. ... tubes are available separately. Per-fit™ ...
Manufactured form the same soft siliconized PVC as all Portex® Blue Line® tracheostomy tubes....
Thermosensitivity of material allows tube to conform to patients anatomy for maximum patient comfort....
Medicine Products: